CRESCENT BIOPHARMA, INC. (CBIO) Operating Margin
- Operating margin · 12 months: Value -1417.74%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1417.74% | Operating income / revenue. Period ending 2026-06-30. $-168.47M ÷ $11.88M × 100 ≈ -1417.74% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -168.47M USD | Operating Income (Loss) |
| Revenue | 11.88M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 152.67M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-168.47M | $11.88M | (m) | $152.67M | (m) | -1417.74% |
| 2026-03-31 | $-163.14M | $11.88M | (m) | $145.36M | (m) | -1372.86% |
| 2025-12-31 | $-152.63M | $10.84M | (m) | $138.09M | (m) | -1407.52% |
| 2025-09-30 | $-68.47M | (m) | (m) | $43.29M | (m) | (m) |
| 2025-06-30 | $-53.82M | (m) | (m) | $24.66M | (m) | (m) |
| 2025-03-31 | $-31.32M | (m) | (m) | $8.25M | (m) | (m) |
| 2024-12-31 | $-40.04M | (m) | (m) | $14.26M | (m) | (m) |
| 2024-09-30 | $-42.30M | (m) | (m) | $19.31M | (m) | (m) |
| 2024-06-30 | $-40.88M | (m) | (m) | $22.89M | (m) | (m) |
| 2024-03-31 | $-39.45M | (m) | (m) | $20.68M | (m) | (m) |
| 2023-12-31 | $-39.28M | (m) | (m) | $20.07M | (m) | (m) |
| 2023-09-30 | $-40.31M | (m) | (m) | $20.67M | (m) | (m) |
| 2023-06-30 | $-39.26M | (m) | (m) | $20.31M | (m) | (m) |
| 2023-03-31 | $-43.68M | (m) | (m) | $24.21M | (m) | (m) |
| 2022-12-31 | $-47.40M | (m) | (m) | $28.39M | (m) | (m) |
| 2022-09-30 | $-54.21M | (m) | (m) | $35.40M | (m) | (m) |
| 2022-06-30 | $-62.78M | (m) | (m) | $43.75M | (m) | (m) |
| 2022-03-31 | $-63.83M | (m) | (m) | $45.95M | (m) | (m) |
| 2021-12-31 | $-63.45M | (m) | (m) | $47.49M | (m) | (m) |
| 2021-09-30 | $-61.59M | (m) | (m) | $46.32M | (m) | (m) |
| 2021-06-30 | $-57.98M | (m) | (m) | $43.70M | (m) | (m) |
| 2021-03-31 | $-57.68M | (m) | (m) | $43.41M | (m) | (m) |
| 2020-12-31 | $-51.51M | (m) | (m) | $44.93M | (m) | (m) |
| 2020-09-30 | $-51.28M | (m) | (m) | $44.68M | (m) | (m) |
| 2020-06-30 | $-51.65M | (m) | (m) | $44.73M | (m) | (m) |
| 2020-03-31 | $-54.36M | (m) | (m) | $47.92M | (m) | (m) |
| 2019-12-31 | $-61.39M | (m) | (m) | $47.03M | (m) | (m) |
| 2019-09-30 | $-61.01M | (m) | (m) | $47.60M | (m) | (m) |
| 2019-06-30 | $-59.43M | (m) | (m) | $46.61M | (m) | (m) |
| 2019-03-31 | $-54.76M | (m) | (m) | $42.84M | (m) | (m) |
| 2018-12-31 | $-51.50M | (m) | (m) | $40.09M | (m) | (m) |
| 2018-09-30 | $-46.08M | (m) | (m) | $34.77M | (m) | (m) |
| 2018-06-30 | $-41.74M | (m) | (m) | $30.82M | (m) | (m) |
| 2018-03-31 | $-37.84M | (m) | (m) | $27.24M | (m) | (m) |
| 2017-12-31 | $-33.93M | (m) | (m) | $24.10M | (m) | (m) |
| 2017-09-30 | $-32.75M | (m) | (m) | $23.44M | (m) | (m) |
| 2017-06-30 | $-32.46M | (m) | (m) | $23.58M | (m) | (m) |
| 2017-03-31 | $-32.31M | (m) | (m) | $23.64M | (m) | (m) |
| 2016-12-31 | $-31.91M | $18.50K | (m) | $23.28M | (m) | -172505.32% |
| 2016-09-30 | $-32.44M | $53.88K | (m) | $24.18M | (m) | -60218.54% |
| 2016-06-30 | $-31.73M | (m) | (m) | $23.30M | (m) | (m) |
| 2016-03-31 | $-13.25M | (m) | (m) | $25.36M | (m) | (m) |
| 2015-12-31 | $-12.78M | $20.07M | (m) | $25.05M | (m) | -63.70% |
| 2015-09-30 | $-11.30M | $20.04M | (m) | $23.37M | (m) | -56.38% |
| 2015-06-30 | $-10.82M | $20.04M | (m) | $23.38M | (m) | -54.02% |
| 2015-03-31 | $-13.15M | $15.03M | (m) | $20.90M | (m) | -87.48% |
| 2014-12-31 | $-11.14M | $15.03M | (m) | $19.57M | $6.60M | -74.13% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-05-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-10.61M | $3.99M | (m) | $11.70M | $2.90M | -265.65% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $3.64M | $15.26M | (m) | $9.44M | $2.18M | 23.82% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |